ImmuCell Appoints Bryan K. Gathagan to Board of Directors
June 21 2023 - 4:05PM
ImmuCell Corporation (Nasdaq: ICCC)
(“ImmuCell” or the “Company”), a growing animal health company that
develops, manufactures and markets scientifically proven and
practical products that improve the health and productivity of
dairy and beef cattle, today announced that Bryan K. Gathagan
has been appointed to its Board of Directors.
Mr. Gathagan is the owner and a managing member of broad
Thinking, LLC, a management consulting firm and has 25 years of
animal health experience. He is a founding member of Animalytix LLC
and has served as its Chief Financial and Chief Technology Officer
since it began operations in 2010. Prior to Animalytix, he was a
senior executive and Vice President of IT and Finance
for Intervet, Inc. and oversaw various finance, IT, and
general business functions between 1998 to 2008, including 3 years
in a global role based in The Netherlands. Before entering the
animal health industry, he served as a Vice President at MBNA and
Norwest Bank responsible for various IT functions and started his
career in IT roles at the University of Maryland, Baltimore
County (UMBC). He holds a BS in Information Systems Management
from UMBC and an MS in Business from Johns Hopkins University.
“Bryan’s depth of experience in the animal health industry and
his financial skills will be a great asset to ImmuCell,” commented
Michael F. Brigham, President and CEO of ImmuCell. “We all look
forward to working with him and adding his perspective to our
business operations and strategies.”
“I’m excited to be joining ImmuCell’s Board of Directors, and I
look forward to supporting Michael and the rest of ImmuCell’s
leadership team,” added Mr. Gathagan.
About ImmuCell:ImmuCell Corporation's
(Nasdaq: ICCC) purpose is to create scientifically
proven and practical products that improve the health and
productivity of dairy and beef cattle. ImmuCell manufactures
and markets First Defense®, providing
Immediate Immunity™ to newborn dairy and beef
calves, and is in the late stages of developing
Re-Tain®, a novel treatment for subclinical
mastitis in dairy cows without a milk discard requirement that
provides an alternative to traditional antibiotics. Press releases
and other information about the Company are available at:
http://www.immucell.com.
Cautionary Note Regarding Forward-Looking Statements
(Safe Harbor
Statement):This Press Release contains or may
contain “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995, as amended.
Forward-looking statements can be identified by the fact that they
do not relate strictly to historical or current facts and will
often include words such as “expects”, “may”, “anticipates”,
“aims”, “intends”, “would”, “could”, “should”, “will”, “plans”,
“believes”, “estimates”, “targets”, “projects”, “forecasts”,
“seeks” and similar words and expressions. These statements are
intended to provide management's current expectation of future
events as of the date of this Press Release, are based on
management's estimates, projections, beliefs and assumptions as of
the date hereof; and are not guarantees of future performance. Such
statements involve known and unknown risks and uncertainties that
may cause the Company's actual results, financial or operational
performance or achievements to be materially different from those
expressed or implied by these forward-looking statements,
including, but not limited to, those risks and uncertainties
detailed from time to time in filings we make with the Securities
and Exchange Commission (SEC), including our Quarterly Reports on
Form 10-Q, our Annual Reports on Form 10-K and our Current Reports
on Form 8-K. In addition, there can be no assurance that future
risks, uncertainties or developments affecting us will be those
that we anticipate. We undertake no obligation to update any
forward-looking statement, whether written or oral, that may be
made from time to time, whether as a result of new information,
future developments or otherwise.
Contacts: |
|
Michael F. Brigham, President and CEOImmuCell Corporation (207)
878-2770Joe Diaz, Robert Blum and Joe DorameLytham Partners,
LLC(602) 889-9700iccc@lythampartners.com |
|
|
|
ImmuCell (NASDAQ:ICCC)
Historical Stock Chart
From Apr 2024 to May 2024
ImmuCell (NASDAQ:ICCC)
Historical Stock Chart
From May 2023 to May 2024